The role of microRNAs and nanoparticles in ovarian cancer: a review

References

• Mody VV, Siwale R, Singh A, et al. Introduction to metallic nanoparticles. J Pharm Bioallied Sci. 2010;2:282.
   PubMedGoogle Scholar
• Kanakkanthara A, Miller JH. MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev. 2013;39:161–170.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.
   PubMed Web of Science ®Google Scholar
• Didžiapetrienė J, Bublevič J, Smailytė G, et al. Significance of blood serum catalase activity and malondialdehyde level for survival prognosis of ovarian cancer patients. Medicina (Kaunas). 2014;50:204–208.
   PubMed Web of Science ®Google Scholar
• Keegan TH, Ries LA, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016;122:1009–1016.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384:1376–1388.
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–725.
   PubMed Web of Science ®Google Scholar
• Ye G, Fu G, Cui S, et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011;124:359–368.
   PubMed Web of Science ®Google Scholar
• Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–679.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145–156.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.
   PubMed Web of Science ®Google Scholar
• Ambros V, Bartel B, Bartel DP, et al. A uniform system for microRNA annotation. RNA. 2003;9:277–279.
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Grocock RJ, Van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(Suppl 1):D140–D1D4.
   Web of Science ®Google Scholar
• Wright MW, Bruford EA. Naming ‘junk’: human non-protein coding RNA (ncRNA) gene nomenclature. Human Genomics. 2011;5:1.
   Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99–110.
   PubMed Web of Science ®Google Scholar
• Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011;91:827–887.
   PubMed Web of Science ®Google Scholar
• Griffiths‐Jones S. The microRNA registry. Nucleic Acids Res. 2004;32(Suppl 1):D109–DD11.
   Web of Science ®Google Scholar
• Zhou X, Ruan J, Wang G, et al. Characterization and identification of microRNA core promoters in four model species. PLoS Comput Biol. 2007;3:e37.
   PubMed Web of Science ®Google Scholar
• Hurteau GJ, Carlson JA, Spivack SD, et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007;67:7972–7976.
   PubMed Web of Science ®Google Scholar
• Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431:343–349.
   PubMed Web of Science ®Google Scholar
• Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res. 2011;39:6845–6853.
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Kafshdooz L, Razban Z, et al. An overview application of silver nanoparticles in inhibition of herpes simplex virus. Artif Cells Nanomed Biotechnol. 2018;46:263–267.
   PubMed Web of Science ®Google Scholar
• Fu L-l, Wen X, Bao J-k, et al. MicroRNA-modulated autophagic signaling networks in cancer. Int J Biochem Cell Biol. 2012;44:733–736.
   PubMed Web of Science ®Google Scholar
• Cho WC. Role of miRNAs in lung cancer. Expert Rev Mol Diagn. 2009;9:773–776.
   PubMed Web of Science ®Google Scholar
• Mehrdad S, Masoud F, Nasim A, et al. Magnetic carbon nanotubes: preparation, physical properties, and applications in biomedicine. Artif Cells Nanomed Biotechnol. 2018 [cited 2017 Oct 18]; [17 p.]. DOI:10.1080/21691401.2017.1389746
   Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635–647.
   PubMed Web of Science ®Google Scholar
• Siva AC, Nelson LJ, Fleischer CL, et al. Molecular assays for the detection of microRNAs in prostate cancer. Mol Cancer. 2009;8:1.
   PubMed Web of Science ®Google Scholar
• Jung M, Mollenkopf HJ, Grimm C, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 2009;13:3918–3928.
   PubMed Web of Science ®Google Scholar
• Tömböl Z, Szabó PM, Molnár V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer. 2009;16:895–906.
   PubMed Web of Science ®Google Scholar
• Panahi Y, Farshbaf M, Mohammadhosseini M, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif Cells Nanomed Biotechnol. 2017;45:788–799.
   PubMed Web of Science ®Google Scholar
• Kumar A, Chandna S. Evidence for a radiation-responsive ‘p53 gateway’ contributing significantly to the radioresistance of lepidopteran insect cells. Sci Rep. 2018;8:2.
   PubMed Web of Science ®Google Scholar
• Chang T-C, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752.
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–743.
   PubMed Web of Science ®Google Scholar
• Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009;114:3872–3879.
   PubMed Web of Science ®Google Scholar
• Ebrahimi E, Akbarzadeh A, Abbasi E, et al. Novel drug delivery system based on doxorubicin-encapsulated magnetic nanoparticles modified with PLGA-PEG1000 copolymer. Artif Cells Nanomed Biotechnol. 2015;44:290–297.
   Web of Science ®Google Scholar
• Kinose Y, Sawada K, Nakamura K, et al. The role of microRNAs in ovarian cancer. BioMed Res Int. 2014;2014:249393.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404.
   PubMed Web of Science ®Google Scholar
• Feng X, Wang Z, Fillmore R, et al. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014;344:166–173.
   PubMed Web of Science ®Google Scholar
• Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009;114:457–464.
   PubMed Web of Science ®Google Scholar
• Shi C, Zhang Z. The prognostic value of the miR‐200 family in ovarian cancer: a meta‐analysis. Acta Obstet Gynecol Scand. 2016;95:505–512.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erozenci A, Smit J, et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81:103–122.
   PubMed Web of Science ®Google Scholar
• Vang S, Wu H-T, Fischer A, et al. Identification of ovarian cancer metastatic miRNAs. PloS One. 2013;8:e58226.
   PubMed Web of Science ®Google Scholar
• Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Tabrizi MHN, Davaran S, Entezami AA. Synthesis of diclofenac polymeric prodrugs and their hydrolysis reactivity. Iran Polym J. 1996;5:243–251.
   Google Scholar
• Davidson B, Tropé CG, Reich R. The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol. 2014;133:640–646.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15:48.
   PubMed Web of Science ®Google Scholar
• Davaran S, Rashidi MR, Pourabbas B, et al. Adriamycin release from poly(lactide-coglycolide)-polyethylene glycol nanoparticles: synthesis, and in vitro characterization. Int J Nanomed. 2006;1:535–539.
   PubMed Web of Science ®Google Scholar
• Xu Y-Z, Xi Q-H, Ge W-L, et al. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14:1057–1060.
   PubMedGoogle Scholar
• Hong F, Li Y, Xu Y, et al. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res. 2013;41:64–71.
   PubMed Web of Science ®Google Scholar
• Shapira I, Oswald M, Lovecchio J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 2014;110:976–983.
   PubMed Web of Science ®Google Scholar
• Meng X, Joosse SA, Müller V, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer. 2015;113:1358–1366.
   PubMed Web of Science ®Google Scholar
• Liang H, Jiang Z, Xie G, et al. Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumor Biol. 2015;36:5305–5313.
   PubMedGoogle Scholar
• Vaksman O, Tropé C, Davidson B, et al. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35:2113–2120.
   PubMed Web of Science ®Google Scholar
• Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PloS One. 2009;4:e5311.
   PubMed Web of Science ®Google Scholar
• Shahab SW, Matyunina LV, Mezencev R, et al. Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach. PLoS One. 2011;6:e22508.
   PubMed Web of Science ®Google Scholar
• Todeschini P, Salviato E, Paracchini L, et al. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts. Cancer Lett. 2017;388:320–327.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690–2695.
   PubMed Web of Science ®Google Scholar
• Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011;458:313–322.
   PubMed Web of Science ®Google Scholar
• Lee C-H, Subramanian S, Beck AH, et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PloS One. 2009;4:e7314.
   PubMed Web of Science ®Google Scholar
• Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci. 2008;105:7004–7009.
   PubMed Web of Science ®Google Scholar
• Davaran S, Rashidi MR, Khandaghi R, et al. Development of a novel prolonged-release nicotine transdermal patch. Pharmacol Res. 2005;51:233–237.
   PubMed Web of Science ®Google Scholar
• Petrillo M, Zannoni G, Beltrame L, Martinelli E, DiFeo A, Paracchini L, et al. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol. 2016;27:625–634.
   PubMed Web of Science ®Google Scholar
• Nasajpour A, Mandla S, Shree S, et al. “Nanostructured fibrous membranes with rose spike-like architecture”. Nano Lett. 2017;17:6235–6240. pp
   PubMed Web of Science ®Google Scholar
• Zhou J, Gong G, Tan H, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015;33:2915–2923.
   PubMed Web of Science ®Google Scholar
• Mostafavi E, Ataie A, Ahmadzadeh M, et al. Synthesis of nano-structured Bi1-xBaxFeO3 ceramics with enhanced magnetic and electrical properties. Mater Chem Phys. 2015;162:106–112.
   Web of Science ®Google Scholar
• Kapetanakis N-I, Uzan C, Jimenez-Pailhes A-S, et al. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival. Oncotarget. 2015;6:36815.
   PubMed Web of Science ®Google Scholar
• Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5:1122.
   PubMed Web of Science ®Google Scholar
• Masliah-Planchon J, Garinet S, Pasmant E. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 2016;7:38892.
   PubMedGoogle Scholar
• Herizchi R, Abbasi E, Milani M, et al. Current methods for synthesis of gold nanoparticles. Artif Cells Nanomed Biotechnol. 2016;44:596–602.
   PubMed Web of Science ®Google Scholar
• Kafshdooz L, Kafshdooz T, Razban Z, et al. The application of gold nanoparticles as a promising therapeutic approach in breast and ovarian cancer. Artif Cells Nanomed Biotechnol. 2016;44:1222–1227.
   PubMed Web of Science ®Google Scholar
• Conde J, Rosa J, Jesús M, et al. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. Biomaterials. 2013;34:2516–2523.
   PubMed Web of Science ®Google Scholar
• Mostafavi E, Ataie A, Ahmadzadeh M. Characterization of nano-structured multiferroic bismuth ferrite produced via solid state reaction route. Adv Mater Res. 2014;829:683–687.
   Google Scholar
• Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011;8:706–713.
   PubMed Web of Science ®Google Scholar
• Li H, Mu Y, Lu J, et al. Target-cell-specific fluorescence silica nanoprobes for imaging and theranostics of cancer cells. Anal Chem. 2014;86:3602–3609.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Baird JR, Tesone AJ, et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012;72:1683–1693.
   PubMed Web of Science ®Google Scholar
• Seviour E, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 2016;35:691–701.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Jung E-J, Shah MY, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013;3:1302–1315.
   PubMed Web of Science ®Google Scholar
• Prahm KP, Novotny GW, Høgdall C, Høgdall E. Current status on microRNAs as biomarkers for ovarian cancer. Apmis. 2016;124:337–355.
   PubMed Web of Science ®Google Scholar
• Mahdian-shakib A, Dorostkar R, Tat M, et al. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Biomed Pharmacother. 2016;84:592–600.
   PubMed Web of Science ®Google Scholar